Role of the factor V Leiden mutation in septic peritonitis assessed in factor V Leiden transgenic mice

Critical Care Medicine

Volumn 34, Issue 8, 2006, Pages 2201-2206

  Brüggemann, Lois W ^a   Schoenmakers, Saskia H H F ^a   Groot, Angelique P ^a   Reitsma, Pieter H ^a   Spek, C Arnold ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Animal experiments; Coagulation; FV Leiden; Inflammation; Sepsis

Indexed keywords

ACTIVATED PROTEIN C; BLOOD CLOTTING FACTOR 5 LEIDEN; INTERLEUKIN 10; INTERLEUKIN 6; THROMBIN ANTITHROMBIN COMPLEX; TUMOR NECROSIS FACTOR ALPHA; ANTITHROMBIN III; ANTITHROMBIN III PROTEASE COMPLEX; ANTITHROMBIN III-PROTEASE COMPLEX; BLOOD CLOTTING FACTOR 5; CYTOKINE; FIBRIN; PEPTIDE HYDROLASE;

ALLELE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL GROWTH; BLOOD VESSEL WALL; CONTROLLED STUDY; ESCHERICHIA COLI; FACTOR V LEIDEN GENE; GENE; GENE MUTATION; GENOTYPE; GRANULOCYTE; HETEROZYGOTE; HOMOZYGOTE; INFLAMMATION; LEUKOCYTE ADHERENCE; LIVER NECROSIS; MALE; MOUSE; NONHUMAN; PERITONEAL CAVITY; PERITONEUM LAVAGE; PERITONITIS; PRIORITY JOURNAL; SEPSIS; TRANSGENIC MOUSE; WILD TYPE; ANIMAL; ASCITES FLUID; BLOOD; CELL ADHESION; DISEASE MODEL; GENETICS; KIDNEY; LEUKOCYTE; LIVER; LUNG; METABOLISM; MICROBIOLOGY; NECROSIS; PATHOLOGY; POINT MUTATION; THROMBOSIS;

ANIMALS; ANTITHROMBIN III; ASCITIC FLUID; CELL ADHESION; CYTOKINES; DISEASE MODELS, ANIMAL; ESCHERICHIA COLI; FACTOR V; FIBRIN; GENOTYPE; GRANULOCYTES; HETEROZYGOTE; HOMOZYGOTE; KIDNEY; LEUKOCYTES; LIVER; LUNG; MICE; MICE, TRANSGENIC; NECROSIS; PEPTIDE HYDROLASES; PERITONEAL LAVAGE; PERITONITIS; POINT MUTATION; SEPSIS; THROMBOSIS;

EID: 33748110996     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.CCM.0000228918.30931.E8     Document Type: Article

References (25)

1. Bertina RM, Koeleman BP, Koster T, et al: Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369:64-67
2. Zöller B, Holm J, Dahlbäck B: Resistance to activated protein C due to a factor V gene mutation: The most common inherited risk factor of thrombosis. Trends Cardiovasc Med 1996; 6:45-53
3. Nicolaes GA, Dahlback B: Factor V and thrombotic disease: Description of a janus-faced protein. Arterioscler Thromb Vasc Biol 2002; 22:530-538
4. Franco RF, Reitsma PH: Genetic risk factors of venous thrombosis. Hum Genet 2001; 109:369-384
5. Lane DA, Mannucci PM, Bauer KA, et al: Inherited thrombophilia: Part 1. Thromb Haemost 1996; 76:651-662
6. Majerus PW: Human genetics. Bad blood by mutation. Nature 1994; 369:14-15
7. Hajjar KA. Factor V: Leiden - An unselfish gene? N Engl J Med 1994; 331:1585-1587
8. Weiler H, Kerlin B, Lytle MC: Factor V Leiden polymorphism modifies sepsis outcome: Evidence from animal studies. Crit Care Med 2004; 32:S233-S238
9. Esmon CT: Interactions between the innate immune and blood coagulation systems. Trends Immunol 2004; 25:536-542
10. van der Poll T, de Jonge E, Levi M: Regulatory role of cytokines in disseminated intravascular coagulation. Semin Thromb Hemost 2001; 27:639-651
11. Levi M, ten Cate H, van der Poll T: Endothelium: Interface between coagulation and inflammation. Crit Care Med 2002; 30:S220-S224
12. Esmon CT: Coagulation and inflammation. J Endotoxin Res 2003; 9:192-198
13. Schoenmakers SH, Reitsma PH, Spek CA: Blood coagulation factors as inflammatory mediators. Blood Cells Mol Dis 2005; 34:30-37
14. Esmon CT, Fukudome K, Mather T, et al: Inflammation, sepsis, and coagulation. Haematologica 1999; 84:254-259
15. Taylor FB, Chank A, Esmon CT, et al: Protein C prevents the coagulopathic and lethal effects of E. coli infusion in the baboon. J Clin Invest 1987; 79:918-925
16. Taylor FB, Peer GT, Lockhart MS, et al: Endothelial cell protein C receptor plays an important role in protein C activation in vivo. Blood 2001; 97:1685-1688
17. Bernard GR, Vincent JL, Laterre PF, et al: Efficacy and safety of recombinant human activated protein C for treatment of patients with severe sepsis. N Engl J Med 2001; 344:699-709
18. Kerlin BA, Yan SB, Isermann BH, et al: Survival advantage associated with heterozygous factor V Leiden mutation in patients with severe sepsis and in mouse endotoxemia. Blood 2003; 102:3085-3092
19. Yan SB, Nelson DR: Effect of factor V Leiden polymorphism in severe sepsis and on treatment with recombinant human activated protein C. Crit Care Med 2004; 32:S239-S246
20. Kondaveeti S, Hibberd ML, Booy R, et al: Effect of the factor V Leiden mutation on the severity of meningococcal disease. Pediatr Infect Dis J 1999; 18:893-896
21. Benfield TL, Dahl M, Nordestgaard BG, et al: Influence of the factor V leiden mutation on infectious disease susceptibility and outcome: A population-based study. J Infect Dis 2005; 192:1851-1857
22. Cui J, Eitzman DT, Westrick RJ, et al: Spontaneous thrombosis in mice carrying the factor V Leiden mutation. Blood 2000; 96:4222-4226
23. Sewnath ME, Olszyna DP, Birjmohun R, et al: IL-10-deficient mice demonstrate multiple organ failure and increased mortality during Escherichia coli peritonitis despite an accelerated bacterial clearance. J Immunol 2001; 166:6323-6331
24. Weijer S, Schoenmakers SH, Florquin S, et al: Inhibition of the tissue factor-factor VIIa pathway does not influence the inflammatory or antibacterial response to Escherichia coli peritonitis in mice. J Infect Dis 2004; 189:2308-2317
25. Schoenmakers SH, Brüggemann LW, Groot AP, et al: Role of coagulation FVIII in septic peritonitis assessed in hemophilic mice. J Thromb Haemost, In Press